GlassScriptPhysician profile
Glen G Daves
NPI 1598850125
$727.04
in general payments reported to CMS, 2019-2025
12 companies · none reported in 2025
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $499 · 2020: $128 · 2021: $99.80.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $344.00 | 2019-2021 | |
| Pfizer INC. | $69.28 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $63.94 | 2019 | |
| Ironwood Pharmaceuticals, INC | $54.32 | 2019-2020 | |
| Abbvie INC. | $50.28 | 2019-2021 | |
| Ucb, INC. | $29.65 | 2019 | |
| Janssen Biotech, INC. | $27.63 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $26.17 | 2019 | |
| Daiichi Sankyo INC. | $19.20 | 2021 | |
| Shire North American Group INC | $14.96 | 2019 | |
| Intercept Pharmaceuticals, INC. | $14.34 | 2020 | |
| Celgene Corporation | $13.27 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Glen Daves listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.